Newsletter sign up


ADC University Our services

ADC Review
is made possible by:



Copyright 2017
Terms & Conditions


Resources for For Clinicians

The information on this page is limited to commercially available antibody-drug conjugates approved by the U.S. Food and Drug Administration (FDA) and intended for U.S. healthcare professionals (HCP) only. If you are not a U.S. HCP, do not continue on this page.


Ado-trastuzumab emtansine (Kadcyla®)

Ado-trastuzumab emtansine (Kadcyla®; Genentech/Roche), as a single agent, is indicated for the treatment of patients with HER2-positive (HER2+), metastatic breast cancer (MBC) who previously received trastuzumab and a taxane, separately or in combination. Patients should have either:

  • Received prior therapy for metastatic disease, or
  • Developed disease recurrence during or within six months of completing adjuvant therapy
Highlights of Prescribing Information English
 Additional Information

English
Reference: [1] KADCYLA Prescribing Information. Genentech, Inc. April 2016

Brentuximab Vedotin (Adcetris®)

Brentuximab vedotin (Adcetris®; Seattle Genetics)  is approved by the U.S. Food and Drug Administration for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy (treatment that reaches and affects the entire body).
The drug is also approved for the treatment of patients with:

  • Classical Hodgkin lymphoma (HL) after failure of autologous hematopoietic stem cell transplantation (auto-HSCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates.
  • Classical HL at high risk of relapse or progression as post auto-HSCT consolidation treatment.
  • Systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen.
  • The sALCL indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
 
 Highlights of Prescribing Information English
 Puntos a Resaltar de La Información de Prescripción Spanish
 Additional information:

English
References [1] ADCETRIS [Prescribing Information]. Bothell, WA: Seattle Genetics, Inc.; September 2016.

Gemtuzumab Ozogamicin (Mylotarg®)

Gemtuzumab Ozogamicin (Mylotarg®; Pfizer) is indicated for the treatment of newly diagnosed CD33-positive acute myeloid leukemia (AML) in adults, and relapsed or refractory CD33-positive AML in adults and pediatric patients 2 years and older.
Highlights of Prescribing Information English
 Additional Information

English
Reference: [1] MYLOTARG Prescribing Information. New York, NY: Pfizer Inc.

Inotuzumab Ozogamicin (Besponsa®)

Inotuzumab ozogamicin (Besponsa®; Pfizer) is the first and only FDA-approved CD22-directed antibody-drug conjugate indicated for the treatment of adults with relapsed or refractory B-cell precursor ALL.
Highlights of Prescribing Information English
 Additional Information

English
Reference: [1] BESPONSA Prescribing Information. New York, NY: Pfizer Inc.

Last Editorial Review: November 23, 2017

Copyright © 2016 – 2017 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.


Manuscript Guidelines & Tips Lonza

Featured Event

Topics to be Covered Introduction To Antibody Conjugates Overview Of Techniques In Quantitative Pharmacology No Such Thing As A Magic Bullet: The Hidden Challenges Of ADC Discovery And Development...


Skip to toolbar